{"url_path":"/sec/grtx/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-225174-index.html","accession_number":"0001193125-26-225174","cik":"0001563577","ticker":"GRTX","issuer_name":"Galera Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-225174-index.html","primary_entity_key":"0001563577","primary_entity_name":"Galera Therapeutics, Inc."},"word_count":118,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n  \nDescription\n\n3.1\n\n  \n[Certificate of Amendment to the Restated Certificate of Incorporation of the Company dated May 11, 2026](d157366dex31.htm)\n\n3.2\n\n  \n[Certificate of Amendment to the Restated Certificate of Incorporation of the Company dated May 12, 2026](d157366dex32.htm)\n\n3.3\n\n  \n[Amended and Restated Bylaws of the Company](d157366dex33.htm)\n\n104\n\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nGALERA THERAPEUTICS, INC.\n\nDate: May 15, 2026\n \n\n \nBy:\n \n\n/s/ J. Mel Sorensen, M.D.\n\n \n\n \n\n \nJ. Mel Sorensen, M.D.\n\n \n\n \n\n \nPresident and Chief Executive Officer"}